## IGFBP2 Antibody IGFBP2 Antibody IGFBP2 Antibody Image: Cell Signal Composition of the second sec

Applications: Rea W, IP	activity: H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 35	Source/Isotype: Rabbit	<b>UniProt ID:</b> #P18065	Entrez-Gene Id: 3485
Product Usage Information		<b>Application</b> Western Blotting Immunoprecipitation			<b>Dilution</b> 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		IGFBP2 Antibody detects endogenous levels of total IGFBP2 protein. It does not cross-react with other IGFBP family members.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the residues at the carboxy-terminal sequence of human IGFBP2. The antibodies are purified by protein A and peptide affinity chromatography.				
Background	Insulin-like growth factor-binding proteins (IGFBPs) play an integral role in modifying insulin-like growth factor (IGF) actions in a wide variety of cell types. This family contains six members that are structurally related but encoded by distinct genes. IGFBPs have a high affinity for IGFs. Some members of the IGFBP family have been consistently shown to inhibit IGF actions by preventing them from gaining access to the IGF receptors, while others potentiate IGF actions by facilitating the ligand- receptor interaction (1-3). IGFBP2 is the second most abundant IGFBP in the circulation and is present in various other biological fluids and tissues of many vertebrate species. Serum IGFBP2 levels are elevated in conditions such as shock, fasting, hypoxemia or after traumata, suggesting complex regulation of IGFBP2 expression (4). IGFBP2 is overexpressed in many malignancies and is often correlated with an increasingly malignant status of the tumor, pointing to a potential involvement of IGFBP2 in tumorigenesis (5).					
Background Referen	ices	1. Duan, C. (2002) <i>J Endocrinol</i> 175, 41-54. 2. Sandhu, M.S. et al. (2002) <i>J Natl Cancer Inst</i> 94, 972-80. 3. Baxter, R.C. (2001) <i>Best Pract Res Clin Endocrinol Metab</i> 15, 421-34. 4. Noel, M. et al. (2001) <i>Curr. Opin. Clin. Nutr. Metab. Care</i> 4, 399-405. 5. Zumkeller, W. (2001) <i>Mol. Pathol.</i> 54, 285-288.				
Species Reactivity		Species reactivity is det	ermined by testin	g in at least one approve	ed application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key	ey W: Western Blotting IP: Immunoprecipitation					
Cross-Reactivity Key		H: Human				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks an more information.	re the property of	their respective owners.	Visit cellsignal.com	/trademarks for
the following terms apply to Products terms and conditions that are in addit				a writing signed by a legally authorized representative of CST, rovided by CST, its affiliates or its distributors. Any Customer's on to, or different from, those contained herein, unless illy authorized representative of CST, are rejected and are of no		

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.